Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
23Andme Holding Co.
(NQ:
ME
)
0.3234
+0.0131 (+4.22%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about 23Andme Holding Co.
< Previous
1
2
3
Next >
23andMe Launches Health Action Plan to Provide Personalized Recommendations Based on Genetic and Other Health Data
October 31, 2023
23andMe+ members will receive customized action plans, from recommended lifestyle changes to clinician-ordered lab tests through 23andMe
From
23andMe, Inc.
Via
GlobeNewswire
23andMe Announces Collaboration Extension with a New Data Licensing Agreement with GSK
October 30, 2023
Following their five year discovery collaboration, 23andMe and GSK have extended their collaboration by entering into a new non-exclusive data licensing agreement, enabling GSK to utilize the 23andMe...
From
23andMe, Inc.
Via
GlobeNewswire
23andMe to Report FY2024 Second Quarter Financial Results
October 25, 2023
From
23andMe, Inc.
Via
GlobeNewswire
Fighting the Silent Killer: Innovative Therapies for Pancreatic Cancer on the Rise
October 23, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(OTCQX:RHHBY),(NASDAQ:BNTX),(NASDAQ:ME) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
Product Safety
23andMe Announces Poster Presentations on 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2023 Annual Meeting
September 27, 2023
23andMe to present data on efficacy and safety and dose selection for the ongoing 23ME-00610 Phase 1/2a clinical trial in patients with advanced solid malignancies
From
23andMe, Inc.
Via
GlobeNewswire
23andMe and Sickle Cell 101 Collaborate to Expand Sickle Cell Awareness Program
September 14, 2023
From
23andMe, Inc.
Via
GlobeNewswire
23andMe Granted New FDA Clearance to Report Additional BRCA Variants
August 31, 2023
From
23andMe, Inc.
Via
GlobeNewswire
23andMe Reports FY2024 First Quarter Financial Results
August 08, 2023
From
23andMe, Inc.
Via
GlobeNewswire
23andMe to Report FY2024 First Quarter Financial Results
July 25, 2023
From
23andMe, Inc.
Via
GlobeNewswire
23andMe Releases New FDA-Cleared Genetic Report on Simvastatin, a Commonly Prescribed Statin
July 20, 2023
From
23andMe, Inc.
Via
GlobeNewswire
23andMe Releases New Report Revealing Genetic Likelihood of Experiencing Panic Attacks
June 21, 2023
With millions of Americans experiencing mental health symptoms, 23andMe+ members now have exclusive access to four mental health reports to help determine their genetic likelihood of having one of...
From
23andMe, Inc.
Via
GlobeNewswire
23andMe Reports FY2023 Fourth Quarter and Full Year Financial Results
May 25, 2023
From
23andMe, Inc.
Via
GlobeNewswire
New 23andMe survey reveals nine out of ten physicians in the U.S. believe genetics play an important part of a patient’s complete health picture
May 16, 2023
From
23andMe, Inc.
Via
GlobeNewswire
23andMe to Report FY2023 Fourth Quarter and Full Year Financial Results
May 11, 2023
From
23andMe Holding Co.
Via
GlobeNewswire
23andMe Releases New Report Revealing Likelihood of Developing Lupus
May 09, 2023
23andMe+ members can now gain insights on the chronic autoimmune condition
From
23andMe Holding Co.
Via
GlobeNewswire
Reza Afkhami Joins 23andMe as Chief Corporate Development Officer
May 08, 2023
Afkhami joins 23andMe with more than 20 years of experience in corporate development and strategy
From
23andMe Holding Co.
Via
GlobeNewswire
23andMe Announces Phase 1 Results from the First-in-Human Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1
April 14, 2023
From
23andMe Holding Co.
Via
GlobeNewswire
Morehouse School of Medicine, Sickle Cell Foundation of Georgia and 23andMe Launch Sickle Cell Carrier Status Awareness Program
April 11, 2023
From
23andMe Holding Co.
Via
GlobeNewswire
23andMe Aims To Raise Awareness of Lipoprotein(a), a Little-Known Genetic Risk Factor for Cardiovascular Disease
March 24, 2023
Company teams up with Novartis on Lipoprotein(a) education for 23andMe customers
From
23andMe Holding Co.
Via
GlobeNewswire
23andMe Announces Presentation of Phase 1 Clinical Data for 23ME-00610, an Investigational Antibody Targeting CD200R1, at the American Association for Cancer Research (AACR) Annual Meeting 2023
March 14, 2023
Data from the Phase 1 portion of the 23ME-00610 Phase 1/2a study, including safety, pharmacokinetics, and the recommended Phase 2a dose to be presented
From
23andMe Holding Co.
Via
GlobeNewswire
New 23andMe Surveys Find Most People and Doctors Agree that Genetic Testing Offers Promise for More Personalized Healthcare
March 09, 2023
From
23andMe Holding Co.
Via
GlobeNewswire
23andMe Announces First Patient Dosed for the Phase 2a Portion of its Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1 in Patients with Advanced Solid Malignancies
February 28, 2023
The expansion portion of the study will evaluate the anti-cancer activity of 23ME-00610 in specific tumor indications, and will further characterize the safety, tolerability, pharmacokinetic and...
From
23andMe Holding Co.
Via
GlobeNewswire
23andMe to Present at Upcoming Investor Conferences
February 22, 2023
From
23andMe Holding Co.
Via
GlobeNewswire
23andMe Reports FY2023 Third Quarter Financial Results
February 08, 2023
From
23andMe Holding Co.
Via
GlobeNewswire
23andMe to Report FY2023 Third Quarter Financial Results
January 26, 2023
From
23andMe Holding Co.
Via
GlobeNewswire
23andMe Survey Shows Majority of People Less Stressed About Their Health During This Holiday Season
December 01, 2022
From
23andMe Holding Co.
Via
GlobeNewswire
The NIH Has Given BioRestorative Therapies A Stamp Of Approval
November 10, 2022
BioRestorative Therapies Inc. (NASDAQ: BRTX) is working on products that may be solutions to conditions that affect millions of Americans with lower back pain and diabetes.
Via
TheNewswire.com
23andMe Reports FY2023 Second Quarter Financial Results
November 07, 2022
From
23andMe Holding Co.
Via
GlobeNewswire
23andMe Trials-in-Progress Poster Details Expansion Cohorts for 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2022 Annual Meeting
November 07, 2022
The presentation outlines plans for the expansion phase of the study (part B), including the specific tumor indications where 23ME-00610 will be tested for anticancer activity
From
23andMe Holding Co.
Via
GlobeNewswire
23andMe Granted New FDA Clearance to Provide Interpretive Drug Information for a Commonly Prescribed Cholesterol Medication
October 27, 2022
FDA 510(k) clearance allows 23andMe to report genetics associated with processing of certain statins, provides interpretive drug information for simvastatin, and removes the requirement for...
From
23andMe Holding Co.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.